Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Says it is facing a delay in a review of label changes to Sublocade by the US Food & Drug Administration. The proposed label has been accepted but the final review has been delayed. Sublocade is a treatment for addiction to opioid drugs. Prior to the announcement, the company’s share price was down 20% in February.

Current stock price: 822.50 pence, up 7.5%

12-month change: down 41%

Copyright 2025 Alliance News Ltd. All Rights Reserved.